295 related articles for article (PubMed ID: 32631094)
1. Updates on the Management of Ocular Vasculopathies with VEGF Inhibitor Conbercept.
Liu H; Ma Y; Xu HC; Huang LY; Zhai LY; Zhang XR
Curr Eye Res; 2020 Dec; 45(12):1467-1476. PubMed ID: 32631094
[No Abstract] [Full Text] [Related]
2. Profile of conbercept in the treatment of neovascular age-related macular degeneration.
Lu X; Sun X
Drug Des Devel Ther; 2015; 9():2311-20. PubMed ID: 25960634
[TBL] [Abstract][Full Text] [Related]
3. Conbercept (KH-902) for the treatment of neovascular age-related macular degeneration.
Nguyen TT; Guymer R
Expert Rev Clin Pharmacol; 2015; 8(5):541-8. PubMed ID: 26289225
[TBL] [Abstract][Full Text] [Related]
4. Anti-vascular endothelial growth factor therapy for ocular neovascular disease.
Andreoli CM; Miller JW
Curr Opin Ophthalmol; 2007 Nov; 18(6):502-8. PubMed ID: 18163003
[TBL] [Abstract][Full Text] [Related]
5. Conbercept for Treatment of Neovascular Age-related Macular Degeneration: Results of the Randomized Phase 3 PHOENIX Study.
Liu K; Song Y; Xu G; Ye J; Wu Z; Liu X; Dong X; Zhang M; Xing Y; Zhu S; Chen X; Shen Y; Huang H; Yu L; Ke Z; Rosenfeld PJ; Kaiser PK; Ying G; Sun X; Xu X;
Am J Ophthalmol; 2019 Jan; 197():156-167. PubMed ID: 30148987
[TBL] [Abstract][Full Text] [Related]
6. Anti-vascular endothelial growth factor treatment for retinal conditions: a systematic review and meta-analysis.
Pham B; Thomas SM; Lillie E; Lee T; Hamid J; Richter T; Janoudi G; Agarwal A; Sharpe JP; Scott A; Warren R; Brahmbhatt R; Macdonald E; Straus SE; Tricco AC
BMJ Open; 2019 May; 9(5):e022031. PubMed ID: 31142516
[TBL] [Abstract][Full Text] [Related]
7. Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease.
Tolentino M
Surv Ophthalmol; 2011; 56(2):95-113. PubMed ID: 21335144
[TBL] [Abstract][Full Text] [Related]
8. Antiangiogenic therapy for ischemic retinopathies.
Al-Latayfeh M; Silva PS; Sun JK; Aiello LP
Cold Spring Harb Perspect Med; 2012 Jun; 2(6):a006411. PubMed ID: 22675660
[TBL] [Abstract][Full Text] [Related]
9. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration.
Eyetech Study Group
Retina; 2002 Apr; 22(2):143-52. PubMed ID: 11927845
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab for choroidal neovascularization secondary to age-related macular degeneration and pathological myopia.
Hashemi S; Faramarzi MA; Ghasemi Falavarjani K; Abdollahi M
Expert Opin Biol Ther; 2014 Dec; 14(12):1837-48. PubMed ID: 25283631
[TBL] [Abstract][Full Text] [Related]
11. [New drug VEGF Trap-Eye--Eylea--and its use in the treatment of age-related macular degeneration, central retinal vein occlusion, diabetic macular edema, and choroidal neovascularization secondary to pathologic myopia].
Rejdak R; Szkaradek M; Taslaq W; Kałuzny JJ; Grieb P; Jünemann AG
Klin Oczna; 2012; 114(4):308-10. PubMed ID: 23461161
[TBL] [Abstract][Full Text] [Related]
12. Five-year visual acuity outcomes and injection patterns in patients with pro-re-nata treatments for AMD, DME, RVO and myopic CNV.
Wecker T; Ehlken C; Bühler A; Lange C; Agostini H; Böhringer D; Stahl A
Br J Ophthalmol; 2017 Mar; 101(3):353-359. PubMed ID: 27215744
[TBL] [Abstract][Full Text] [Related]
13. Clinical efficacy of conbercept injection on neovascular age-related macular degeneration under different levels of inflammation.
Zhang X; Zhuang X; Dong J; Fu B; Zhang G; Xu L
Adv Clin Exp Med; 2024 Apr; 33(4):335-342. PubMed ID: 37747440
[TBL] [Abstract][Full Text] [Related]
14. Trends of Anti-Vascular Endothelial Growth Factor Use in Ophthalmology Among Privately Insured and Medicare Advantage Patients.
Parikh R; Ross JS; Sangaralingham LR; Adelman RA; Shah ND; Barkmeier AJ
Ophthalmology; 2017 Mar; 124(3):352-358. PubMed ID: 27890437
[TBL] [Abstract][Full Text] [Related]
15. Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES).
Wu L; Martínez-Castellanos MA; Quiroz-Mercado H; Arevalo JF; Berrocal MH; Farah ME; Maia M; Roca JA; Rodriguez FJ;
Graefes Arch Clin Exp Ophthalmol; 2008 Jan; 246(1):81-7. PubMed ID: 17674014
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of conbercept in neovascular age-related macular degeneration: results from a 12-month randomized phase 2 study: AURORA study.
Li X; Xu G; Wang Y; Xu X; Liu X; Tang S; Zhang F; Zhang J; Tang L; Wu Q; Luo D; Ke X;
Ophthalmology; 2014 Sep; 121(9):1740-7. PubMed ID: 24793528
[TBL] [Abstract][Full Text] [Related]
17. Safety review of anti-VEGF therapy in patients with myopic choroidal neovascularization.
Ng DSC; Ho M; Iu LPL; Lai TYY
Expert Opin Drug Saf; 2022 Jan; 21(1):43-54. PubMed ID: 34228553
[TBL] [Abstract][Full Text] [Related]
18. Intravitreal conbercept for choroidal neovascularisation secondary to pathological myopia in a real-world setting in China : Intravitreal conbercept was safe and effective in treating myopic choroidal neovascularization.
Nie X; Wang Y; Yi H; Qiao Y
BMC Ophthalmol; 2021 Mar; 21(1):116. PubMed ID: 33663431
[TBL] [Abstract][Full Text] [Related]
19. Recent trends in anti-vascular endothelial growth factor intravitreal injections: a large claims database study in Japan.
Hashimoto Y; Okada A; Matsui H; Yasunaga H; Aihara M; Obata R
Jpn J Ophthalmol; 2023 Jan; 67(1):109-118. PubMed ID: 36508060
[TBL] [Abstract][Full Text] [Related]
20. [What can anti-VEGF therapy achieve in clinical routine? : Effectiveness of anti-VEGF therapy in patients with macular diseases in clinical routine on 1492 eyes in Austria].
Wiesinger K; Reinelt P; Ennemoser A; Edelmayr M; Schönherr U
Ophthalmologe; 2017 Jul; 114(7):639-645. PubMed ID: 27815675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
